Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. The Company performs impairment tests related to its goodwill on an annual basis or when certain triggering events or circumstances are identified that would more likely than not reduce the estimated fair value of the goodwill below its carrying amount.

Due to the significant decrease in the Company’s publicly quoted share price and market capitalization during the second quarter fiscal year 2023, the Company accelerated its annual impairment test and performed a quantitative test of its goodwill as of July 31, 2022 that resulted in a $5.8 million non-cash impairment charge during the second quarter of fiscal year 2023.

As a result of continued significant decrease in the Company’s publicly quoted share price and market capitalization during the third quarter of fiscal year 2023, the Company performed a quantitative impairment test of its goodwill as of October 31, 2023. Based on this quantitative test, the Company incurred a non-cash impairment charge during the third quarter of fiscal year 2023 of $3.3 million, which represents impairment of the entire remaining balance of the Company's goodwill.

The following table represents the changes in goodwill since January 31, 2021:


	Goodwill
	(Amounts in thousands)
Balance as of January 31, 2021	$	10,577
Translation adjustment		(695	)
Balance as of January 31, 2022		9,882
Translation adjustment		(784	)
Impairment		(9,098	)
Balance as of January 31, 2023	$	—

The Company’s finite-lived intangible assets were fully amortized as of January 31, 2023 and 2022.

In fiscal year 2022, the Company recognized $0.8 million and $0.5 million of amortization expense for intangible assets in selling and marketing and research and development functions, respectively.